These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21739822)

  • 1. The breast cancer hormone receptor retesting controversy in Newfoundland and Labrador, Canada: lessons for the health system.
    Gregory DM; Parfrey PS
    Healthc Manage Forum; 2010; 23(3):114-8. PubMed ID: 21739822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The estrogen receptor/progesterone receptor testing errors in Newfoundland and Labrador: a journey of hope, health, and healing.
    Chubbs K
    Healthc Manage Forum; 2013; 26(4):196-9. PubMed ID: 24696944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes.
    Ross JS; Symmans WF; Pusztai L; Hortobagyi GN
    Clin Cancer Res; 2007 May; 13(10):2831-5. PubMed ID: 17504980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inept laboratory work botched cancer patients' results, inquiry finds.
    Spurgeon D
    BMJ; 2009 Mar; 338():b952. PubMed ID: 19273507
    [No Abstract]   [Full Text] [Related]  

  • 5. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing.
    Hede K
    J Natl Cancer Inst; 2008 Jun; 100(12):836-7, 844. PubMed ID: 18544732
    [No Abstract]   [Full Text] [Related]  

  • 6. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
    Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
    Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone receptor expression in breast cancer: postanalytical issues.
    Lee M; Lee CS; Tan PH
    J Clin Pathol; 2013 Jun; 66(6):478-84. PubMed ID: 23526546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry.
    Yaziji H; Taylor CR; Goldstein NS; Dabbs DJ; Hammond EH; Hewlett B; Floyd AD; Barry TS; Martin AW; Badve S; Baehner F; Cartun RW; Eisen RN; Swanson PE; Hewitt SM; Vyberg M; Hicks DG;
    Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):513-20. PubMed ID: 18931614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
    Colleoni M; Viale G; Zahrieh D; Pruneri G; Gentilini O; Veronesi P; Gelber RD; Curigliano G; Torrisi R; Luini A; Intra M; Galimberti V; Renne G; Nolè F; Peruzzotti G; Goldhirsch A
    Clin Cancer Res; 2004 Oct; 10(19):6622-8. PubMed ID: 15475452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen and progesterone receptors in breast cancer.
    Yip CH; Rhodes A
    Future Oncol; 2014 Nov; 10(14):2293-301. PubMed ID: 25471040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
    Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
    Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
    Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer care Ontario guideline recommendations for hormone receptor testing in breast cancer.
    Nofech-Mozes S; Vella ET; Dhesy-Thind S; Hanna WM
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):684-96. PubMed ID: 22608362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASO Author Reflections: Core Needle Biopsy and Hormonal Receptor Retesting in Breast Cancer: Controversy and Management.
    Zhu S; Chen X; Shen K
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):731-732. PubMed ID: 32661856
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach.
    Dekker TJ; ter Borg S; Hooijer GK; Meijer SL; Wesseling J; Boers JE; Schuuring E; Bart J; van Gorp J; Bult P; Riemersma SA; van Deurzen CH; Sleddens HF; Mesker WE; Kroep JR; Smit VT; van de Vijver MJ
    Breast Cancer Res Treat; 2015 Jul; 152(2):247-52. PubMed ID: 26041687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer. Study Group on Hormone Receptors using Immunohistochemistry FNCLCC/AFAQAP. National Federation of Centres to Combat Cancer/French Association for Quality Assurance in Pathology].
    Balaton AL; Coindre JM; Collin F; Ettore F; Fiche M; Jacquemier J; Le Doussal V; Mandard AM; Mathieu MC; Migeon C; Simony-Lafontaine J; Treilleux I; Verriele V; Vilain MO; Zafrani B
    Ann Pathol; 1996; 16(2):144-8. PubMed ID: 8767687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunocytochemical determination of estrogen and progesterone receptors on 219 fine-needle aspirates of breast cancer. A prospective study.
    Marrazzo A; Taormina P; Leonardi P; Lupo F; Filosto S
    Anticancer Res; 1995; 15(2):521-6. PubMed ID: 7763033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.